Cerus Corporation announced it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. The agreement covers Cerus' entire INTERCEPT product line, which includes pathogen reduction technology for platelets, plasma, and the INTERCEPT Fibrinogen Complex (IFC). The arrangement is designed to expand access to these products among BCA's 60+ member blood centers, which collectively produce about half of the U.S. platelet and cryoprecipitate supply. The agreement also includes a resource-sharing model to facilitate production and distribution of IFC, as well as collaborative training and education initiatives to increase awareness and adoption of pathogen reduction technologies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210895691) on December 10, 2025, and is solely responsible for the information contained therein.
Comments